---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021256"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:53:34.480278+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ProKidney Q1 net loss $36.9M, cash $463.7M; Phase 2 REACT enrollment complete

## Summary
- Net loss before noncontrolling interest $36.9M vs $67.5M in Q1 2022; R&D spend $25.6M.
- Cash, cash equivalents and marketable securities $463.7M as of March 31, 2023.
- Completed enrollment in REGEN-007 Phase 2 study (53 subjects); initial data expected late 2023.
- Phase 3 proact 1 enrollment ongoing; interim data targeted by end of 2024.
- Preparing to initiate proact 2 Phase 3 study in EU, Latin America, Asia Pacific in H2 2023.

## SEC filing metadata
- accession: 0000950170-23-021256
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000095017023021256/0000950170-23-021256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000095017023021256/prok-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021256
- JSON: https://secwatch.observer/filing/0000950170-23-021256.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021256.txt

## Key facts
- Earnings Releases
  PROKIDNEY CORP. reported the first quarter ended March 31, 2023 results: net income $36.9 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: $36.9 million
  - Result: reported results
  source text: On May 11, 2023, ProKidney Corp. issued a press release to announce its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000095017023021256/0000950170-23-021256-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.